# Haleon PLC (HLN.L) Stock Analysis: Evaluating the 14% Upside Potential

- Link: https://www.directorstalkinterviews.com/haleon-plc-hln-l-stock-analysis-evaluating-the-14-upside-potential/4121245721
- Published: 2026-03-23T05:14:17+00:00
- Author: Katherine Hargreaves

Haleon PLC (HLN.L) stands out in the healthcare sector with a formidable market 
capitalization of $33.46 billion. As an integral player in the Drug Manufacturers–
Specialty & Generic industry, Haleon’s extensive portfolio of consumer healthcare
products has positioned it as a significant entity across several global markets,
including North America, Europe, and the Asia Pacific.

Currently trading at 375.7 GBp, Haleon’s price has seen a minor dip of 0.01% recently,
reflecting a price change of -3.50 GBp. Despite this slight downturn, the stock 
remains within its 52-week range of 326.60 GBp to 415.20 GBp. Analysts are optimistic,
projecting an average target price of 428.56 GBp, which suggests a potential upside
of 14.07%. This optimistic outlook is bolstered by 12 buy ratings, 3 hold ratings,
and only 2 sell ratings, indicating strong investor confidence.

A closer examination of Haleon’s financial health reveals some intriguing insights.
The company boasts a solid revenue growth rate of 0.60% and a notable Return on 
Equity of 10.27%, underscoring effective management and operational efficiency. 
Furthermore, Haleon generates a robust free cash flow of approximately $1.4 billion,
providing a strong foundation for potential reinvestment and shareholder distributions.

Despite the absence of a trailing P/E ratio, the forward P/E stands at an unusually
high 1,662.17. This suggests that investors anticipate significant future earnings
growth, a testament to Haleon’s strategic initiatives and market positioning. The
company’s EPS of 0.18 further supports this growth narrative.

Haleon’s dividend yield of 1.89% is an attractive aspect for income-focused investors,
especially with a sustainable payout ratio of 36.76%. This indicates Haleon’s commitment
to returning value to shareholders while maintaining sufficient capital for growth
opportunities.

Technically, the stock is trading below its 50-day moving average of 386.07 GBp 
but remains above the 200-day moving average of 367.48 GBp. The RSI of 44.71 suggests
that the stock is neither overbought nor oversold, offering a balanced entry point
for potential investors. However, the MACD indicator of -3.35, lagging behind the
signal line at -2.71, warrants caution as it may suggest short-term bearish momentum.

Founded in 1715 and headquartered in Weybridge, United Kingdom, Haleon has a rich
history and a comprehensive portfolio of trusted brands like Sensodyne, Centrum,
and Advil. The company continues to leverage its deep-rooted expertise to innovate
and expand its product offerings in the consumer healthcare market. This strategic
focus on research and development, coupled with robust distribution channels, positions
Haleon to capture further market share in emerging regions.

For investors, Haleon presents a compelling investment opportunity, backed by its
strong market position, promising growth prospects, and stable financials. The potential
upside of 14.07%, coupled with solid analyst endorsements, makes it a noteworthy
consideration for those looking to diversify their portfolio with a resilient healthcare
stock. As with any investment, it’s crucial to conduct thorough due diligence and
consider current market conditions before making investment decisions.

Share on: